FAQs

November 30, 2020November 30, 2020

FAQs About the aHUS Registry

FAQs

You may be considering enrolling in the ongoing global atypical hemolytic uremic syndrome (aHUS) registry. Here are some frequently asked questions and answers about the registry to help you learn more ... Read more

July 27, 2020November 30, 2020

FAQs About Soliris for aHUS

FAQs

Soliris (eculizumab) is a medication developed by Alexion to treat atypical hemolytic uremic syndrome (aHUS). Here are some frequently asked question and answers about Soliris: How does Soliris work? In ... Read more

July 20, 2020July 27, 2020

FAQs About Ultomiris for aHUS

FAQs

Ultomiris (ravulizumab-cwvz) is a treatment for atypical hemolytic uremic syndrome (aHUS) that was developed by Alexion. The therapy is designed to treat people with low levels of circulating red blood cells. ... Read more

April 30, 2020May 4, 2020

FAQs About Dialysis in aHUS

FAQs

Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by the formation of blood clots in the small blood vessels of the kidneys. The kidneys filter waste out of ... Read more

February 13, 2020February 14, 2020

FAQs About Kidney Transplants for Patients With aHUS

FAQs

Atypical hemolytic uremic syndrome (aHUS) is a rare genetic disease associated with symptoms such as hemolytic anemia (loss of red blood cells) and thrombocytopenia (low platelet count). In severe cases, ... Read more

August 29, 2019April 21, 2020

FAQs About aHUS

FAQs

Information about rare diseases such as atypical hemolytic uremic syndrome (aHUS) can be difficult to find, complicating the situation for both patients and caregivers. Here are answers to some of ... Read more